Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 19.75 GBp
Change Today -0.25 / -1.25%
Volume 392.3K
TRX On Other Exchanges
As of 11:35 AM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

tissue regenix group plc (TRX) Snapshot

19.50 GBp
Previous Close
20.00 GBp
Day High
20.00 GBp
Day Low
19.50 GBp
52 Week High
07/30/14 - 29.00 GBp
52 Week Low
04/14/15 - 14.50 GBp
Market Cap
Average Volume 10 Days
-0.01 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for TISSUE REGENIX GROUP PLC (TRX)

Related News

No related news articles were found.

tissue regenix group plc (TRX) Related Businessweek News

No Related Businessweek News Found

tissue regenix group plc (TRX) Details

Tissue Regenix Group Plc, a medical devices company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United Kingdom and the United States. The company’s patented decellularisation (dCELL) technology process removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold, which can be used to repair diseased or worn-out body parts. The dCELL technology has applications in various clinical needs, such as wound care, heart valve replacement, and knee repair. It offers DermaPure, a decellularized human dermis product used to cover chronic wounds; and vascular patches for peripheral vascular reconstruction. The company also develops OrthoPure category products, which include meniscus products used to repair damages in the meniscus knee cartilage, as well as tendon products for anterior cruciate ligament repairs. In addition, it develops CardioPure HV, a human heart valve product. Tissue Regenix Group Plc was incorporated in 2006 and is based in York, the United Kingdom.

60 Employees
Last Reported Date: 05/11/15
Founded in 2006

tissue regenix group plc (TRX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 248.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 179.0K GBP
Compensation as of Fiscal Year 2015.

tissue regenix group plc (TRX) Key Developments

Tissue Regenix Group Plc Announces Further Medicare Coverage Approval for DermaPure®

Tissue Regenix Group plc announced that it has secured approval from the Noridian Healthcare Solutions and Palmetto GBA Medicare administrators for DermaPure® reimbursement. The approval from Noridian Healthcare Solutions and Palmetto GBA means that DermaPure® is now available to 20.7 million Medicare beneficiaries across 30 states and follows previously announced approvals from the Novitas Solutions and CGS Administrators jurisdictions in 2015. Gaining Medicare approval for DermaPure® across the United States is a key element of Tissue Regenix's strategy for full commercialisation of the product and allows the company to access the large potential group of US patients who would be unable to benefit from Tissue Regenix products without it. The Medicare programme in the United States is a national social insurance programme which provides health insurance for citizens aged 65 and over. It is administered by bodies such as Noridian Healthcare Solutions and Palmetto GBA, each one with their own jurisdiction of states. When coverage is approved it enables medical establishments to purchase and seek reimbursement for products used to treat post-acute and outpatients who are beneficiaries of the Medicare initiative.

Tissue Regenix Group Plc, Annual General Meeting, Jun 12, 2015

Tissue Regenix Group Plc, Annual General Meeting, Jun 12, 2015., at 10:00 GMT Standard Time. Location: DLA Piper UK LLP, Princes Exchange. Agenda: To receive the company's annual accounts, strategic report and directors' and auditors' reports for the year ended 31 January 2015; to reappoint John Samuel, who retires by rotation, as a director of the Company; to reappoint Antony Odell, who retires by rotation, as a director of the Company; to reappoint Alan Miller, who retires by rotation, as a director of the Company; to reappoint KPMG LLP as auditors of the Company; to authorise the directors to determine the remuneration of the auditors; and to transact such other business issues.

Tissue Regenix Group plc Reports Unaudited Consolidated Earnings Results for the Year Ended January 31, 2015

Tissue Regenix Group Plc reported unaudited consolidated earnings results for the year ended January 31, 2015. For the year, on the consolidated basis, the company reported operating income of £100,000 compared with £6,000 a year ago. Operating loss was £8,369,000 compared with £6,577,000 a year ago. Loss before taxation was £8,201,000 compared with £6,303,000 a year ago. Loss after tax attributable to equity holders of the parent was £7,581,000 or 1.19 pence basic and diluted per share compared with £5,593,000 or 0.88 pence basic and diluted per share a year ago. Net cash outflow from operations was £8,285,000 compared with £5,647,000 a year ago. Purchases of property, plant and equipment was £114,000 compared with £358,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRX:LN 19.75 GBp -0.25

TRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation TRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,332.2x
Price/Book 11.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,587.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TISSUE REGENIX GROUP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at